{"id":8793,"date":"2025-10-17T16:24:27","date_gmt":"2025-10-17T08:24:27","guid":{"rendered":"https:\/\/regask.com\/?p=8793"},"modified":"2025-10-17T16:24:27","modified_gmt":"2025-10-17T08:24:27","slug":"nouveau-programme-pilote-de-la-fda-susceptible-de-transformer-lavenir-de-la-fabrication-de-medicaments-generiques-aux-etats-unis","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/","title":{"rendered":"Nouveau programme pilote de la FDA qui pourrait remodeler l\u2019avenir de\u2026"},"content":{"rendered":"<p>The <a href=\"https:\/\/www.fda.gov\/\"><strong>U.S. Food and Drug Administration (FDA)<\/strong><\/a> has announced a <strong>pilot prioritization program<\/strong> for <strong>Abbreviated New Drug Applications (ANDAs)<\/strong> that supports <strong>domestic manufacturing and testing<\/strong>. The initiative, launched on <strong>October 3, 2025<\/strong>, aims to <strong>expedite review timelines<\/strong> for qualifying applications, <strong>reduce foreign dependency<\/strong>, and <strong>boost the resilience of the U.S. pharmaceutical supply chain<\/strong>.<\/p>\n<p>Under the pilot, generic drug manufacturers who conduct <strong>bioequivalence testing within the United States<\/strong>, produce <strong>finished dosage forms domestically<\/strong>, and source <strong>active pharmaceutical ingredients (APIs)<\/strong> exclusively from <strong>U.S.-based suppliers<\/strong> are eligible for <strong>priority review<\/strong>.<\/p>\n<p>This measure addresses both <strong>public health and national security risks<\/strong> by strengthening domestic R&amp;D capabilities and reducing the inspection of costs and delays associated with overseas manufacturing facilities.<\/p>\n<div class=\"row\"  id=\"row-1439597815\">\n\n\t<div id=\"col-1222565381\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Key Provisions and Eligibility<\/h3>\n\t<div id=\"gap-2055939125\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2055939125 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>To qualify for <strong>priority review<\/strong>, ANDA applicants must fulfill <strong>all three<\/strong> of the following criteria:<\/p>\n<ol>\n<li>Conduct or obtain a waiver for <strong>bioequivalence testing<\/strong> in the U.S.<\/li>\n<li><strong>Manufacture finished dosage forms<\/strong><\/li>\n<li>Use <strong>API suppliers located in the U.S. <\/strong><a href=\"https:\/\/natlawreview.com\/article\/fda-launches-new-anda-prioritization-pilot-support-us-based-generic-manufacturing\"><strong><sup>[1]<\/sup><\/strong><\/a><\/li>\n<\/ol>\n<p>Applicants must reference <a href=\"https:\/\/www.fda.gov\/media\/89061\/download#:~:text=This%20MAPP%20describes%20how%20the%20review%20of%20original,Original%20ANDAs%2C%20Amendments%2C%20and%20Supplements%20%28January%2030%2C%202020%29.\"><strong>FDA\u2019s Manual of Policies and Procedures (MAPP) 5240.3<\/strong><\/a> when requesting prioritization under this pilot program. The program is open-ended, with <strong>no specified deadline<\/strong> for participation, allowing ongoing submissions under this framework.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1222565381 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-621599799\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Why It Matters<\/h3>\n\t<div id=\"gap-724380648\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-724380648 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>The pilot program represents a <strong>strategic shift toward onshoring critical pharmaceutical operations<\/strong>. With <strong>over 50% of pharmaceuticals distributed in the U.S. manufactured overseas<\/strong> and only <strong>9% of API manufacturers based domestically<\/strong>, <a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-public-meeting-onshoring-manufacturing-drugs-and-biological-products-09302025\"><sup>[2]<\/sup><\/a> this initiative supports <strong>supply chain security<\/strong>, <strong>faster market access for generics<\/strong>, and <strong>enhanced regulatory efficiency<\/strong>.<\/p>\n<p>By incentivizing local production and testing, the FDA aims to <strong>bolster public health infrastructure<\/strong>, <strong>stimulate domestic R&amp;D<\/strong>, and <strong>mitigate risks linked to international supply disruptions<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-621599799 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1293281809\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Who Should Take Note<\/h3>\n\t<div id=\"gap-912480584\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-912480584 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>This update is particularly relevant for <strong>regulatory affairs<\/strong>, <strong>quality assurance<\/strong>, and <strong>manufacturing operations teams<\/strong> within generic drug companies. Organizations preparing ANDA submissions should assess their <strong>manufacturing geography, testing practices, and supplier base<\/strong> to determine eligibility for the <strong>FDA\u2019s expedited review pathway<\/strong>.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1293281809 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-2001390547\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h3>Next Steps<\/h3>\n\t<div id=\"gap-617831017\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-617831017 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Stakeholders are advised to:<\/p>\n<ul>\n<li>Review their manufacturing and testing workflows against the pilot\u2019s eligibility requirements.<\/li>\n<li>Reference <strong>MAPP 5240.3<\/strong> when submitting ANDAs to request prioritization.<\/li>\n<li>Maintain supporting documentation to demonstrate compliance with domestic sourcing and testing standards.<\/li>\n<\/ul>\n<p>For teams navigating regulatory submissions or preparing for shifting U.S. compliance frameworks, leveraging predictive and automated intelligence tools can ensure timely action and submission accuracy.<\/p>\n<p><a href=\"https:\/\/regask.com\/\"><strong>RegASK<\/strong><\/a> is a leading <strong>agentic AI regulatory intelligence and workflow orchestration platform<\/strong> that empowers global organizations in <strong>highly regulated sectors<\/strong>, including <strong>life sciences and consumer goods<\/strong>, to proactively navigate complex regulatory landscapes. By leveraging <strong>experts in the loop<\/strong>, RegASK delivers <strong>predictive actionable insights<\/strong>, <strong>end-to-end automation<\/strong>, and <strong>real-time compliance tracking<\/strong> across <strong>140+ countries <\/strong>streamlining submissions like ANDAs and accelerating market access.<br \/>\n<a href=\"https:\/\/regask.com\/product\/\"><strong>Learn more<\/strong><\/a><strong> or <\/strong><a href=\"https:\/\/regask.com\/book-a-demo\/\"><strong>book a demo now.<\/strong><\/a><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2001390547 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-2010643878\">\n\n\t<div id=\"col-1917426544\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQs<\/h3>\n\t<div id=\"gap-1249337545\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1249337545 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4>What is the FDA\u2019s new pilot program about?<\/h4>\n\t<div id=\"gap-650306345\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-650306345 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>The program prioritizes review of ANDAs for generic drugs manufactured and tested in the U.S., aiming to strengthen domestic production and reduce reliance on foreign suppliers.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1917426544 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1668876358\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>What are the eligibility criteria for priority review?<\/h4>\n\t<div id=\"gap-1953127600\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1953127600 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>ANDA applicants must conduct bioequivalence testing in the U.S., manufacture finished dosage forms domestically, and source APIs exclusively from U.S.-based suppliers.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1668876358 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-816742186\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>Is there a submission deadline for this pilot program?<\/h4>\n\t<div id=\"gap-1257701095\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1257701095 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>No, the FDA has not specified a deadline. Eligible ANDAs can be submitted on an ongoing basis under the pilot framework.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-816742186 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1388157212\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4>How can RegASK support organizations with this FDA initiative?<\/h4>\n\t<div id=\"gap-1137751240\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1137751240 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><a href=\"https:\/\/regask.com\/\">RegASK<\/a> Helps manufacturers and compliance teams monitor evolving FDA policies, automate documentation workflows, and align submission strategies with programs like the FDA\u2019s prioritization pilot to ensure faster, compliant market entry.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1388157212 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-856365719\">\n\n\t<div id=\"col-1904965493\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>References<\/h3>\n\t<div id=\"gap-661445406\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-661445406 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<ol>\n<li><a href=\"https:\/\/natlawreview.com\/article\/fda-launches-new-anda-prioritization-pilot-support-us-based-generic-manufacturing\">Natlawreview &#8211; FDA Launches New ANDA Prioritization Pilot to Support U.S.-Based Generic Manufacturing<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-public-meeting-onshoring-manufacturing-drugs-and-biological-products-09302025\">gov &#8211; FDA Public Meeting: Onshoring Manufacturing of Drugs and Biological Products<\/a><\/li>\n<\/ol>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1904965493 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has announced a pilot prioritization program for Abbreviated New Drug Applications (ANDAs) that supports domestic manufacturing and testing. The initiative, launched on October 3, 2025, aims to expedite review timelines for qualifying applications, reduce foreign dependency, and boost the resilience of the U.S. pharmaceutical supply chain. Under the&#8230;<\/p>","protected":false},"author":32,"featured_media":8794,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[527,33],"tags":[],"class_list":["post-8793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-united-states-regulations","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.7 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>New FDA Pilot Program to Transform Drug Manufacturing<\/title>\n<meta name=\"description\" content=\"Explore the New FDA Pilot Program that could reshape the future of U.S. generic drug manufacturing and enhance supply chains.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/nouveau-programme-pilote-de-la-fda-susceptible-de-transformer-lavenir-de-la-fabrication-de-medicaments-generiques-aux-etats-unis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New FDA Pilot Program that Could Reshape the Future of U.S. Generic Drug Manufacturing\" \/>\n<meta property=\"og:description\" content=\"Explore the New FDA Pilot Program that could reshape the future of U.S. generic drug manufacturing and enhance supply chains.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/nouveau-programme-pilote-de-la-fda-susceptible-de-transformer-lavenir-de-la-fabrication-de-medicaments-generiques-aux-etats-unis\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T08:24:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Hannah Nordin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hannah Nordin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\"},\"author\":{\"name\":\"Hannah Nordin\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\"},\"headline\":\"New FDA Pilot Program that Could Reshape the Future of &hellip;\",\"datePublished\":\"2025-10-17T08:24:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\"},\"wordCount\":809,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\",\"articleSection\":[\"United States\",\"Regulatory News\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\",\"name\":\"New FDA Pilot Program to Transform Drug Manufacturing\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\",\"datePublished\":\"2025-10-17T08:24:27+00:00\",\"description\":\"Explore the New FDA Pilot Program that could reshape the future of U.S. generic drug manufacturing and enhance supply chains.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png\",\"width\":800,\"height\":600,\"caption\":\"New Fda Pilot Program Could Reshape Future Us Generic Drug Manufacturing\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/3a8aaee2c7585284f97ec9e038e36b65\",\"name\":\"Hannah Nordin\",\"sameAs\":[\"https:\\\/\\\/regask.com\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nouveau programme pilote de la FDA pour transformer la fabrication de m\u00e9dicaments","description":"D\u00e9couvrez le nouveau programme pilote de la FDA qui pourrait remodeler l\u2019avenir de la fabrication de m\u00e9dicaments g\u00e9n\u00e9riques aux \u00c9tats-Unis et am\u00e9liorer les cha\u00eenes d\u2019approvisionnement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/nouveau-programme-pilote-de-la-fda-susceptible-de-transformer-lavenir-de-la-fabrication-de-medicaments-generiques-aux-etats-unis\/","og_locale":"fr_FR","og_type":"article","og_title":"New FDA Pilot Program that Could Reshape the Future of U.S. Generic Drug Manufacturing","og_description":"Explore the New FDA Pilot Program that could reshape the future of U.S. generic drug manufacturing and enhance supply chains.","og_url":"https:\/\/regask.com\/fr\/nouveau-programme-pilote-de-la-fda-susceptible-de-transformer-lavenir-de-la-fabrication-de-medicaments-generiques-aux-etats-unis\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2025-10-17T08:24:27+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","type":"image\/png"}],"author":"Hannah Nordin","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Hannah Nordin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#article","isPartOf":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/"},"author":{"name":"Hannah Nordin","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65"},"headline":"New FDA Pilot Program that Could Reshape the Future of &hellip;","datePublished":"2025-10-17T08:24:27+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/"},"wordCount":809,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","articleSection":["United States","Regulatory News"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/","url":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/","name":"Nouveau programme pilote de la FDA pour transformer la fabrication de m\u00e9dicaments","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","datePublished":"2025-10-17T08:24:27+00:00","description":"D\u00e9couvrez le nouveau programme pilote de la FDA qui pourrait remodeler l\u2019avenir de la fabrication de m\u00e9dicaments g\u00e9n\u00e9riques aux \u00c9tats-Unis et am\u00e9liorer les cha\u00eenes d\u2019approvisionnement.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/new-fda-pilot-program-that-could-reshape-the-future-of-u-s-generic-drug-manufacturing\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/10\/new-fda-pilot-program-could-reshape-future-us-generic-drug-manufacturing.png","width":800,"height":600,"caption":"New Fda Pilot Program Could Reshape Future Us Generic Drug Manufacturing"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/3a8aaee2c7585284f97ec9e038e36b65","name":"Hannah Nordin","sameAs":["https:\/\/regask.com"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/8793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=8793"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/8793\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/8794"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=8793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=8793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=8793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}